Bio Green Med Solution Financials - Benzinga

Bio Green Med Solution Inc

BGMSNASDAQ

Trade with Public

Trade with Public

$0.8906

0.00310.35%

Last update: Aug 27, 4:58 PM

$0.8739

-0.0136-1.53%

Overview News Earnings ForecastFinancialsSentiment Ownership Compare Stock Report

Bio Green Med Solution Financials

Bio Green Med Solution (BGMS) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Bio Green Med Solution Q2 EPS $(0.08) Up From $(0.93) YoY, Sales $336.000K

Bio Green Med Solution (NASDAQ:BGMS) reported quarterly losses of $(0.08) per share. This is a 91.4 percent increase over losses of $(0.93) per share from the same period last year. The company reported $336.000

Benzinga Newsdesk

PRO
Cyclacel Pharmaceuticals Q1 EPS $(0.04) Up From $(11.52) YoY, Sales $778.000K

Cyclacel Pharmaceuticals (NASDAQ:BGMS) reported quarterly losses of $(0.04) per share. This is a 99.65 percent increase over losses of $(11.52) per share from the same period last year. The company reported $778.000

Benzinga Newsdesk

PRO
Bio Green Med Solution Q4 EPS $(2.21) Up From $(847.61) YoY, Sales $666.000K

Bio Green Med Solution (NASDAQ:BGMS) reported quarterly losses of $(2.21) per share. This is a 99.74 percent increase over losses of $(847.61) per share from the same period last year. The company reported $666.000

Benzinga Newsdesk

PRO
Bio Green Med Solution Q3 EPS $(1.31) Up From $(2.70) YoY, Sales $81.000K Up From $10.000K YoY

Bio Green Med Solution (NASDAQ:BGMS) reported quarterly losses of $(1.31) per share. This is a 51.48 percent increase over losses of $(2.70) per share from the same period last year. The company reported $81.000

Benzinga Newsdesk